Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSH01-TCR-T in Refractory/Recurrent Solid Tumors
NCT05539833Phase 1Recruiting
- Sponsor
- TScan Therapeutics, Inc.
- Start
- Aug 2022
- Primary completion
- Jul 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KSH01-TCR-T in solid tumor, sponsored by TScan Therapeutics, Inc. Primary endpoints: Treatment-related adverse events at 2 years and Changes in overall tumor diameter at 2 years. Started Aug 2022; status: recruiting.
02
Drugs
KSH01-TCR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05539833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539833.